Johnson & Johnson (JNJ) Current Deferred Tax Assets (2009 - 2015)
Johnson & Johnson's (JNJ) quarterly Current Deferred Tax Assets came in at $3.6 billion in Q3 2015, down 5.77% year-over-year from $3.8 billion in Q3 2014, and down 3.14% quarter-over-quarter from $3.7 billion in Q2 2015.
Analysis
Johnson & Johnson (JNJ) Current Deferred Tax Assets (2009 - 2015) Analysis & Trends
Johnson & Johnson has disclosed Current Deferred Tax Assets across 7 years of filings, most recently posting $3.6 billion for Q3 2015.
- In Q3 2015, Current Deferred Tax Assets fell 5.77% year-over-year to $3.6 billion; the TTM figure through Sep 2015 stood at $3.6 billion (down 5.77% YoY), while the FY2014 annual figure was $3.6 billion, down 1.11% from the prior year.
- Current Deferred Tax Assets came in at $3.6 billion for Q3 2015 at Johnson & Johnson, down from $3.7 billion in the prior quarter.
- In the past five years, Current Deferred Tax Assets ranged from a high of $4.1 billion in Q2 2014 to a low of $2.2 billion in Q1 2011.
- Average Current Deferred Tax Assets over 5 years is $3.2 billion, with a median of $3.3 billion recorded in 2012.
- Year-over-year, Current Deferred Tax Assets fell 20.37% in 2011 and jumped 35.17% in 2012.
- Over 5 years, Current Deferred Tax Assets stood at $2.5 billion in 2011, then advanced by 26.57% to $3.1 billion in 2012, then climbed by 14.91% to $3.6 billion in 2013, then decreased by 1.11% to $3.6 billion in 2014, then climbed by 1.09% to $3.6 billion in 2015.
- Per Business Quant data, the three most recent Current Deferred Tax Assets figures were $3.6 billion in Q3 2015, $3.7 billion in Q2 2015, and $3.5 billion in Q1 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 27, 2015 | 3.61 Bn |
| Jun 28, 2015 | 3.72 Bn |
| Mar 29, 2015 | 3.52 Bn |
| Dec 28, 2014 | 3.57 Bn |
| Sep 28, 2014 | 3.83 Bn |
| Jun 29, 2014 | 4.10 Bn |
| Mar 30, 2014 | 3.92 Bn |
| Dec 29, 2013 | 3.61 Bn |
| Sep 29, 2013 | 3.49 Bn |
| Jun 30, 2013 | 3.28 Bn |
| Mar 31, 2013 | 3.09 Bn |
| Dec 30, 2012 | 3.14 Bn |
| Sep 30, 2012 | 3.25 Bn |
| Jul 1, 2012 | 3.12 Bn |
| Apr 1, 2012 | 2.70 Bn |
| Jan 1, 2012 | 2.56 Bn |
| Oct 2, 2011 | 2.48 Bn |
| Jul 3, 2011 | 2.31 Bn |
| Apr 3, 2011 | 2.27 Bn |
| Jan 2, 2011 | 2.22 Bn |